Changes in Beneficial Ownership · 4
Medicus Pharma Ltd.
MDCXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
es260854079_4-smitha.xml
Filing details
- Report period
- 2026-11-13
- Issuer
- Medicus Pharma Ltd.
- Issuer CIK
- 0001997296
- Trading symbol
- MDCX
Reporting owner 1
- Name
- Smith Andrew Alasdair
- Reporting owner CIK
- 0001309614
- Relationship
- Officer
- Officer title
- Chief Operating Officer
- Address
- 300 CONSHOHOCKEN STATE ROAD, SUITE 200, W. CONSHOHOCKEN, PA, 19428
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Shares, no par value | 2026-11-13 | A · Form 4[F1] | 14,534 | A | 1.72 | 29,243 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- On November 13, 2026, Andrew A. Smith entered into a subscription agreement with the Issuer, pursuant to which Mr. Smith agreed to purchase 14,534 common shares, no par value, at a purchase price of $1.72 per share in a private placement in which other investors also participated under separate subscription agreements.↩ 1
Signature 1
- Signed
- /s/ Raza Bokhari, as Attorney-in-Fact, for Andrew A. Smith
- Date
- 2026-11-17
Company context
We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").